| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) and paclitaxel - (IMpassion131) | Triple-negative breast cancer (TNBC) | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | ACTEMRA (tocilizumab) - (COVACTA) | Coronavirus COVID-19 | Phase 3 | Intravenous | COVID-19 | |
| Roche Holding AG ADR | Etrolizumab HIBISCUS I | Ulcerative colitis | Phase 3 | Subcutaneous | Gastroenterology | |
| Roche Holding AG ADR | Ipatasertib - IPATential150 | Castration-resistant prostate cancer | Phase 3 | Oral | Oncology | |
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) - IMaGYN050 | Ovarian cancer | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) - IMvigor130 | Urothelial carcinoma | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) plus chemotherapy | Urothelial carcinoma | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) - IMvigor010 | Urothelial cancer | Phase 3 | Intravenous | Oncology |